474: Ozempic och Viktväktarnas kollaps
Summary
In this episode of Kapitalet, hosts Jakob Urschell and Rickard Almqvist explore the rise and fall of Novo Nordisk, the Danish pharmaceutical giant behind the GLP-1 weight loss drugs Ozempic and Wegovy. They trace the decades of scientific research that led to these breakthroughs, highlighting how the company briefly became Europe's most valuable firm before facing intense competition from Eli Lilly’s Zepbound. The discussion also covers the cultural impact of these medications, the collapse of Weight Watchers, and the broader societal implications of treating obesity as a chronic disease ra…
Topics discussed
Sponsors: PVC, IKEA, and Obesity Initiative
School drop-off chat: Intermittent fasting results
Reality TV: Sveriges dummaste människa
Intro: The rise of GLP-1 drugs and Novo Nordisk
Sponsor: Bybit and the 1971 end of Bretton Woods
Diabetes history: Type 1 vs 2 and insulin research
GLP-1 discovery: From lizards to Amelyn's 2005 drug
Novo Nordisk origins: Marie Krag and insulin pens
Saxenda launch: First GLP-1 drug for obesity
Semaglutid breakthrough: Weekly injections and 15% loss
Wegovy launch: Stigma reduction and celebrity usage
Market dominance: Novo Nordisk vs Denmark's GDP
Weight Watchers history: From support groups to franchise
Eli Lilly enters: Tirzepatide and the 'Surpass' study
Market shift: Zepbound overtakes Wegovy in US
Patent cliffs and off-label use of GLP-1 drugs
Broader health impacts and societal changes
Weight Watchers bankruptcy and pivot to GLP-1 distribution
Conclusion: Diabetes tech progress and future outlook
Sponsors: Norwegian Air and Polestar
Listen ad-free on Castria